Marketing in life sciences fails for a reason that has nothing to do with creativity: the agency did not understand that every claim has to survive a review process, and that the review process is not an obstacle to route around but the actual shape of the work. Whether you sell instruments to laboratories, reagents to researchers, software to clinical teams or a regulated therapeutic, your audience is small, technical, and unusually good at spotting a claim without evidence. This page covers what changes when the buyer is a scientist, which regulatory lines a marketer has to know exists, and how to test whether an agency has really worked in the sector or has simply read about it.
The audience is small, technical and unforgiving
A life sciences market is often measured in thousands of buyers worldwide, not millions, and many of them are reachable by name. That inverts the usual playbook. Reach metrics matter less than depth: a technical note that answers a real method question, a webinar with an actual application scientist, or a comparison against the alternative your buyer is already using. Copy written by a generalist reads as hollow to a principal investigator within two sentences, so the practical question for an agency is who writes. Ask whether they employ or retain writers with laboratory or clinical backgrounds, and ask to see a technical piece they produced without your subject matter expert rewriting it. Ask also how they plan to reach a specialty audience where broad targeting simply wastes budget.
Regulated claims change what marketing can say
The constraint depends on what you sell, and an agency should be able to state yours back to you. Promotional material for prescription drugs falls under FDA oversight, and the agency's Office of Prescription Drug Promotion exists to review and act on promotional communications for prescription medicines. Devices, diagnostics and research use only products each carry their own limits, most importantly the line between a research product and one promoted for clinical decisions. Where a product is outside FDA jurisdiction, general advertising law still applies, and the FTC expects health related claims to be supported by competent and reliable scientific evidence before they are made. An agency that treats medical, legal and regulatory review as an approvals bottleneck rather than a design input will produce work that dies in review, repeatedly, and bill you for it.
How the work is bought and scoped
Sector agencies usually price a monthly retainer covering strategy, content and campaign management, with product launches scoped separately as projects because they carry a compressed timeline and a heavier review load. Congress and conference activity is normally its own line, since booth content, pre show outreach and follow up run on the event calendar rather than the retainer month. Many life sciences companies buy the ongoing content and search work as combined digital marketing and SEO services and keep scientific review in house, which is a sensible split provided the review capacity actually exists. Ask how many review cycles the fee assumes, because that single assumption explains most scope disputes in this sector, and ask what happens to the fee when your reviewers take four weeks rather than one.
How to test sector experience
Ask for two examples where the agency navigated a review process, and ask what got cut and why. The answer is revealing, because an agency that has genuinely worked in regulated markets will talk fluently about substantiation, references and claim hierarchies, while one that has not will talk about brand storytelling. Ask which scientific conferences they have supported, which journals and trade publications they buy in, and how they handle a customer testimonial in a setting where a clinical anecdote can become an off label promotional claim. Finally ask who owns the content library at the end, since a well built claims and asset library is one of the more valuable things an engagement produces and it should not leave with the agency.
Questions people ask about life sciences marketing
Do we need a specialist agency or will a strong B2B firm work?
It depends on regulatory exposure. For research tools and laboratory software, a strong technical B2B agency plus your own scientific reviewers often works well. Where promotion touches prescription products or clinical claims, the review environment is specialised enough that experience in it is worth paying for, because the cost of rework is high.
How should content approval be structured?
Agree in advance who reviews, in what order, and how many cycles the fee assumes. Give the agency a claims library with the supporting references attached so writers start from approved language rather than inventing it. Most delays come from unclear ownership of the final sign off, not from reviewers being slow.
Is search worth investing in for a niche scientific product?
Often yes, because the searches are low in volume but extremely specific, and the person typing a protocol question or a catalogue number is much closer to purchase than any display audience. The economics depend on your order value, so measure enquiries and quote requests rather than traffic.
Who is responsible if a claim goes too far?
The company whose product is promoted. Agencies can be asked to fix material, but regulatory exposure sits with the manufacturer or sponsor. That is why review is a design input rather than a final gate, and why your agreement should require substantiation to be identified alongside every claim as the copy is drafted.